tbuckley/cabot-search huggingface dataset:
Health authority misused doctors' funds NHS issues code of practice on openness General practices should audit their nursing services BMA criticises increase in fees for part time medical services Filling public health posts at regional level
Authors: L. Beecham
Journal: BMJ (1995)

# Health authority misused doctors' {#article-title-2}

The High Court has ruled that Manchester Family Health Services Authority (FHSA) illegally used pounds sterling250 000 intended for general practitioners. Instead of the funds being used to reimburse doctors for employing staff and improving premises the authority employed eight facilitators to help with administration and publicity.

Allowing an application for a judicial review, Mr Justice Collins said that he had not received “a totally satisfactory explanation” about the role of the facilitators after they were appointed on three year contracts in 1991. He had been told that they were connected with clinics and general health care. When Manchester Local Medical Committee (LMC) had asked whether the funds had been used to pay for the facilitators “they received a denial which was undoubtedly false.” The judge added that the money could not as a matter of law be used in the way that it was used. He refused to allow the health secretary to carry out any further inquiry. The general manager and the chairman of the FHSA at the time had resigned and there was no legal provision under which he could order repayment of the money.

Welcoming the decision, the secretary of the LMC, Dr David Shlosberg, said, “Our funds have been plundered for trendy services which had no clear purpose and which people did not want—and some of which were seemingly not delivered.” He believed that similar things were happening in other areas.

A spokesman for the Manchester Health Commission, of which the FHSA forms a part, said that he understood that the judge was only being asked …
Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma
Authors: Yifeng Xia, Jingjing Wei, Songsong Zhao, Beibei Guo, Fenghua Meng, Bert Klumperman, Zhiyuan Zhong
Journal: Journal of Controlled Release (2021)
The Outcome of Childhood B-Cell Precursor ALL with ETV6-RUNX1 Treated with Japan Association of Childhood Leukemia Study (JACLS) ALL-02 Trial
Authors: Ikuya Usami, Toshihiko Imamura, Yoshihiro Takahashi, So-ichi Suenobu, Daiichiro Hasegawa, Yoshiko Hashii, Takao Deguchi, Tsukasa Hori, Akira Shimada, Koji Kato, Etsuro Ito, Akiko Moriya Saito, Hirohide Kawasaki, Hiroki Hori, Keiko Yumura Yagi, Jun-ichi Hara, Atsushi Sato, Keizo Horibe
Journal: Blood (2017)
Monocytic Differentiation and AHR Signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia
Authors: Kyle A. Romine, Tamilla Nechiporuk, Daniel Bottomly, Sophia Jeng, Shannon K. McWeeney, Andy Kaempf, M. Ryan Corces, Ravindra Majeti, Jeffrey W. Tyner
Journal: Blood Cancer Discovery (2021)

Abstract To understand mechanisms of response to BET inhibitors (BETi), we mined the Beat AML functional genomic data set and performed genome-wide CRISPR screens on BETi-sensitive and BETi-resistant acute myeloid leukemia (AML) cells. Both strategies revealed regulators of monocytic differentiation—SPI1, JUNB, FOS, and aryl-hydrocarbon receptor signaling (AHR/ARNT)—as determinants of BETi response. AHR activation synergized with BETi, whereas inhibition antagonized BETi-mediated cytotoxicity. Consistent with BETi sensitivity dependence on monocytic differentiation, ex vivo sensitivity to BETi in primary AML patient samples correlated with higher expression of the monocytic markers CSF1R, LILRs, and VCAN. In addition, HL-60 cell line differentiation enhanced its sensitivity to BETi. Further, screens to rescue BETi sensitivity identified BCL2 and CDK6 as druggable vulnerabilities. Finally, monocytic AML patient samples refractory to venetoclax ex vivo were significantly more sensitive to combined BETi + venetoclax. Together, our work highlights mechanisms that could predict BETi response and identifies combination strategies to overcome resistance. Significance: Drug resistance remains a challenge for AML, and new therapies, such as BETi, will require combination approaches to boost single-agent responses. We conducted genome-wide CRISPR screens and functional genomics on AML patient samples to identify leukemic differentiation state and AHR signaling as primary mediators of BETi response. This article is highlighted in the In This Issue feature, p. 403
Survey Regarding Academic vs Private Practice Surgeons—A Gold Mine of Information
Authors: Carlo Maria Rosati, Panos N. Vardas
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Will Ending the Medicaid Drug Rebate Cap Lower Drug Prices?
Authors: Benjamin N. Rome, Aaron S. Kesselheim
Journal: JAMA Internal Medicine (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
High Incidence of CMV Reactivation after Haploidentical Donor Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide, and Its Impact on Transplant Outcomes
Authors: Monzr M. Al Malki, Sanjeet Dadwal, Dongyun Yang, Sally Mokhtari, Thai Cao, Ketevan Gendzekhadze, Ibrahim Aldoss, Pablo Parker, Margaret R. O'Donnell, David S. Snyder, David Senitzer, Joseph Rosenthal, Auayporn P. Nademanee, Don Diamond, John Zaia, Stephen J. Forman, Ryotaro Nakamura
Journal: Blood (2017)
当院における血栓吸引カテーテル“Thrombuster”の使用成績
Authors: 高橋亨, 佐藤直利, 倉田知師央, 神津英至, 西原昌宏, 古橋真人, 坂本賢一, 林学, 西谷隆宏
Journal: Circulation (2004)
The relationship of smoking with ace2 and COVID-19
Authors: W. Li, Y. Zhou
Journal: American Journal of Respiratory and Critical Care Medicine (2021)

RATIONALE: Respiratory epithelium expressing angiotensin-converting enzyme 2 (ACE2) is the entry for novel coronavirus, pathogen of the outbreaking pneumonia (COVID-19). Although a few recent studies have found different ACE2 expression in lung tissue of smokers. The effect of smoking on ACE2 expression and COVID-19 is still not clear. So, we did this research to determine the effect of smoking on ACE2 expression pattern and its relationship with COVID-19. Methods: The clinical data of COVID-19 patients with smoking and non-smoking were analysed, and ACE2 expression of respiratory and digestive mucosa epitheliums from smoker and non-smoker patients or healthy subjects were detected by Immunohistochemistry (IHC) staining.Results: only 24 (8.1%) Of 295 laboratory-confirmed COVID-19 patients, were current smokers with moderate smoking or above, which accouted for 54.2% of severe cases with higher motality than non-smokers (8.3% vs 0.4%, p=0.018). Data analysis showed that the proportion of smokers in COVID-19 was lower than that in general population of China (Z=11.65, P<0.001). IHC staining showed downregulated ACE2 expression in respiratory and digestive epitheliums of smokers. Conclusions: The proportion of smokers in COVID-19 patients was lower, which may be explained by ACE2 downregulation in respiratory mucosa epitheliums. However, smoking COVID-19 patients accounted for higher proportion in severe cases and higher motality than non-smoking COVID-19 patients, which need to be noticed.
Epidemiologic Analysis of Chilblains Cohorts Before and During the COVID-19 Pandemic
Authors: Patrick E. McCleskey, Bree Zimmerman, Amara Lieberman, Liyan Liu, Cynthia Chen, Farzam Gorouhi, Christine C. Jacobson, David S. Lee, Achyuth Sriram, Amanda Thornton, Arnd M. Herz, Paradi Mirmirani, Lisa J. Herrinton
Journal: JAMA Dermatology (2021)

Beginning in March 2020, case reports and case series linked the COVID-19 pandemic with an increased occurrence of chilblains, but this association has not been evaluated in an epidemiologic study.To assess whether a correlation exists between COVID-19 incidence and chilblains incidence.A retrospective cohort study was conducted within the Kaiser Permanente Northern California system from January 1, 2016, to December 31, 2020; health plan members of all ages were included.COVID-19 incidence in 207 location-months, representing 23 geographic locations in northern California across 9 months.Chilblains incidence was the main outcome. The association of chilblains incidence with COVID-19 incidence across the 207 location-months was measured using the Spearman rank correlation coefficient.Of 780 patients with chilblains reported during the pandemic, 464 were female (59.5%); mean (SD) age was 36.8 (21.8) years. COVID-19 incidence was correlated with chilblains incidence at 207 location-months (Spearman coefficient 0.18; P = .01). However, only 17 of 456 (3.7%) patients with chilblains tested during the pandemic were positive for SARS-CoV-2, and only 9 of 456 (2.0%) were positive for SARS-CoV-2 within 6 weeks of the chilblains diagnosis. Test results of 1 of 97 (1.0%) patients were positive for SARS-CoV-2 IgG antibodies. Latinx patients were disproportionately affected by COVID-19 but not by chilblains.This cohort study found that in northern California, the incidence of chilblains increased during the pandemic but was correlated weakly with the incidence of COVID-19 across 207 location-months. These findings may have resulted from a causal role of COVID-19, increased care-seeking by patients with chilblains during the pandemic, or changes in behavior during shelter in place.
Attenuation of tonic inhibition prevents chronic neurovascular impairments in a Thy1-ChR2 mouse model of repeated, mild traumatic brain injury
Authors: James R Mester, Paolo Bazzigaluppi, Adrienne Dorr, Tina Beckett, Matthew Burke, JoAnne McLaurin, John G Sled, Bojana Stefanovic
Journal: Theranostics (2021)

Rationale: Mild traumatic brain injury (mTBI), the most common type of brain trauma, frequently leads to chronic cognitive and neurobehavioral deficits. Intervening effectively is impeded by our poor understanding of its pathophysiological sequelae. Methods: To elucidate the long-term neurovascular sequelae of mTBI, we combined optogenetics, two-photon fluorescence microscopy, and intracortical electrophysiological recordings in mice to selectively stimulate peri-contusional neurons weeks following repeated closed-head injury and probe individual vessel's function and local neuronal reactivity. Results: Compared to sham-operated animals, mTBI mice showed doubled cortical venular speeds (115 ± 25%) and strongly elevated cortical venular reactivity (53 ± 17%). Concomitantly, the pericontusional neurons exhibited attenuated spontaneous activity (-57 ± 79%) and decreased reactivity (-47 ± 28%). Post-mortem immunofluorescence revealed signs of peri-contusional senescence and DNA damage, in the absence of neuronal loss or gliosis. Alteration of neuronal and vascular functioning was largely prevented by chronic, low dose, systemic administration of a GABA-A receptor inverse agonist (L-655,708), commencing 3 days following the third impact. Conclusions: Our findings indicate that repeated mTBI leads to dramatic changes in the neurovascular unit function and that attenuation of tonic inhibition can prevent these alterations. The sustained disruption of the neurovascular function may underlie the concussed brain's long-term susceptibility to injury, and calls for development of better functional assays as well as of neurovascularly targeted interventions.
Ultrasound definition of enthesitis in spondyloarthritis and psoriatic arthritis: arrival or starting point?
Authors: Emilio Filippucci, Gianluca Smerilli, Andrea Di Matteo, Walter Grassi
Journal: Annals of the Rheumatic Diseases (2021)

Enthesitis has a key role in the diagnosis, classification and management of patients with spondyloarthritis and psoriatic arthritis. Clinical assessment of enthesitis is known to be inaccurate mainly due to its poor specificity. In this context, ultrasound has the potential to improve the evaluation of enthesitis and, therefore, the management of patients with spondyloarthritis and psoriatic arthritis. In this viewpoint, we review the Outcome Measures in Rheumatology (OMERACT) definitions for ultrasound enthesitis, highlighting their current limits and potential implications on rheumatology research and clinical practice.
Abstract 375: Utility of Routine Early Head Computed Tomography Following Non-Traumatic Out-Of Hospital Cardiac Arrest
Authors: Bradley J Petek, David E Hamilton, Lindsay G Panah, Philip E Dormish, Sean R Mendez, Elizabeth K Stevenson, David Cardona Estrada, Michael G Silverman
Journal: Circulation (2019)

Introduction: Head computed tomography (CT) is frequently performed in survivors of out-of-hospital cardiac arrest (OHCA). However, the clinical utility of routine, early head CT in these patients is not well understood. We sought to characterize the associations between findings on early head CT with presenting characteristics and outcomes in survivors of OHCA. Hypothesis: Presence of early intracranial swelling is associated with poor outcomes. Methods: This is a retrospective analysis from a multicenter cohort of 432 patients with non-traumatic OHCA between 2/1/17 through 4/1/19. Patients were included if they underwent head CT &lt;24 hrs after return of spontaneous circulation. Head CT findings were based on reads performed by local radiologists. Intracranial swelling was defined as loss of gray-white matter differentiation, sulcal effacement, and/or cerebral edema. Underlying cause of OHCA was adjudicated by trained physicians. Baseline characteristics and outcomes were compared between those with and without intracranial swelling. Result: Early head CT (&lt;24 hrs) was performed in 378 (87.5%) patients with OHCA. Intracranial swelling was present in 97 (25.7%) patients with early head CT, and 14 (3.7%) had evidence of intracranial hemorrhage (ICH, Table). Of the patients presenting with ICH, 3/14 (21.4%) had shockable rhythms, 7/14 (50%) had subarachnoid hemorrhage, and ICH was the adjudicated cause of arrest in 10/14 (71.4%) patients. Patients with intracranial swelling were younger, less likely to have presented with a shockable rhythm, cardiac etiology, and witnessed OHCA. They were more likely to have a suppressed EEG, anoxia on MRI, and were less likely to survive to hospital discharge. Conclusions: In survivors of non-traumatic OHCA, routine, early (&lt;24 hrs) head CT identified ICH in 3.7% of patients, and ICH was the adjudicated cause of arrest in 2.6% of patients. Intracranial swelling was present in more than 1/4 of patients, and associated with poor outcomes.
Abstract LB115: Blocking p27Kip1phosphorylation with a liposomal:peptide drug induces Reactive Oxygen Species,necroptosis and tumor regression in breast cancer cells
Authors: Stacy Wister Blain, Irina Jilishitz, Jason L. Quinones, Priyank Patel, Grace Chen, Jared Pavetsky, Allison VanInwegen VanInwegen, Scott Schoninger, Manasi P. Jogalekar, Vladislav Tsiperson, Lingyue Yan, Yun Wu, Susan R. Gottesman, Jonathan Somma
Journal: Cancer Research (2021)

Abstract Resistance to cyclin D-cdk4/6 inhibitors (CDK4/6i) represents an unmet clinical need and is frequently caused by compensatory CDK2 activity. Here we describe a novel strategy to prevent CDK4i resistance by using a therapeutic liposomal:peptide formulation, NP-ALT, to inhibit the tyrosine phosphorylation of p27Kip1(CDKN1B), which in turn inhibits both CDK4/6 and CDK2. We find that NP-ALT blocks proliferation in HR+ breast cancer (BC) cells, as well as CDK4i-resistant cell types, including Triple Negative (TN) BC. The peptide ALT is not as stable in primary mammary epithelium, suggesting that NP-ALT has little effect in non-tumor tissues. In HR+ BC cells specifically, NP-ALT treatment induces ROS and RIPK1-dependent necroptosis. Estrogen signaling and ERα appear required. Significantly, NP-ALT induces necroptosis in MCR7 ESRY537S cells, which contain an ER gain of function mutation frequently detected in metastatic patients, which renders them resistant to endocrine therapy. Here we show that NP-ALT causes necroptosis and tumor regression in treatment naïve, palbociclib-resistant and endocrine-resistant BC cells and xenograft models, demonstrating that p27 is a viable therapeutic target to combat drug resistance. Because the RAS/MAPK axis is the target of many therapies, NP-ALT, with its ability to target p27, can deal with the backend drug resistance seen in the presence of other inhibitors, extending the addressable market of this line of therapy. Citation Format: Stacy Wister Blain, Irina Jilishitz, Jason L. Quinones, Priyank Patel, Grace Chen, Jared Pavetsky, Allison VanInwegen VanInwegen, Scott Schoninger, Manasi P. Jogalekar, Vladislav Tsiperson, Lingyue Yan, Yun Wu, Susan R. Gottesman, Jonathan Somma. Blocking p27Kip1phosphorylation with a liposomal:peptide drug induces Reactive Oxygen Species,necroptosis and tumor regression in breast cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr LB115.
Exome sequencing in obsessive–compulsive disorder reveals a burden of rare damaging coding variants
Authors: Mathew Halvorsen, Jack Samuels, Ying Wang, Benjamin D. Greenberg, Abby J. Fyer, James T. McCracken, Daniel A. Geller, James A. Knowles, Anthony W. Zoghbi, Tess D. Pottinger, Marco A. Grados, Mark A. Riddle, O. Joseph Bienvenu, Paul S. Nestadt, Janice Krasnow, Fernando S. Goes, Brion Maher, Gerald Nestadt, David B. Goldstein
Journal: Nature Neuroscience (2021)
Interpreting a lateral flow SARS-CoV-2 antigen test
Authors: Oliver T Mytton, Noel McCarthy, Jessica Watson, Penny Whiting
Journal: BMJ (2021)

### What you need to know

Lateral flow devices (LFDs) are being used to test asymptomatic people for covid-19 as part of the approach in the UK and elsewhere to control the spread of the disease and to enable society to reopen.1234

The risks and benefits of using LFDs for widespread testing of asymptomatic people are the subject of ongoing uncertainty and debate.1567 Despite concerns about accuracy, LFD tests continue to be widely used. In the week ending 19 May, 4.9 million registered tests were undertaken in England.8 People taking a test receive advice on what their result means and what they should do; however, the widespread use of these tests means doctors may increasingly be asked about them (for example, when patients with a recent result present to services). This practice pointer considers how to interpret and communicate results from LFD tests based on our current understanding of the tests’ performance.

Lateral flow devices can detect the presence of a target substance in a liquid, typically in a single use disposable …
Патогенетична роль зниження резистентності слизового бар’єра при коморбідному перебігу пептичної виразки дванадцятипалої кишки та ГЕРХ
Authors: L.M. Mosiychuk, A.I. Rudenko, O.P. Petishko, L.V. Demeshkina
Journal: GASTROENTEROLOGY (2013)

Установлено, що загострення пептичної виразки дванадцятипалої кишки й гастроезофагеальної рефлюксної хвороби (ГЕРХ) характеризується вірогідним зниженням резистентності слизового бар’єра гастродуоденальної зони внаслідок посилення деградації сіалопротеїнів, колагенових білків, зниження продукції фукопротеїнів слизу, активації перекисного окиснення ліпідів і зниження антиоксидантного захисту слизової оболонки. Доповнення антисекреторної терапії мелатоніном при поєднанні пептичної виразки дванадцятипалої кишки й ГЕРХ сприяє покращенню психосоматичного стану і покращенню факторів захисту слизової оболонки езофагогастродуоденальної зони.
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Authors: Renata Ferrarotto, Moran Amit, Priyadharsini Nagarajan, M. Laura Rubin, Ying Yuan, Diana Bell, Adel K. El-Naggar, Jason M. Johnson, William H. Morrison, David I. Rosenthal, Bonnie S. Glisson, Faye M. Johnson, Charles Lu, Frank E. Mott, Bita Esmaeli, Eduardo M. Diaz, Paul W. Gidley, Ryan P. Goepfert, Carol M. Lewis, Randal S. Weber, Jennifer A. Wargo, Sreyashi Basu, Fei Duan, Shalini S. Yadav, Padmanee Sharma, James P. Allison, Jeffrey N. Myers, Neil D. Gross
Journal: Clinical Cancer Research (2021)

In locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN), surgery followed by radiotherapy is standard but can be cosmetically and functionally devastating, and many patients will have recurrence.